Hirtle Callaghan & Co’s Biogen BIIB Stock Holding History

Hirtle Callaghan & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-88	Closed	-$28K	–	159
2017 Q3	$28K	Hold	88	–	–	﹤0.01%	126
2017 Q2	$24K	Sell	88 -22	-20%	-$5.82K	﹤0.01%	115
2017 Q1	$30K	Sell	110 -600	-85%	-$170K	﹤0.01%	116
2016 Q4	$202K	Sell	710 -77	-10%	-$22.8K	0.04%	23
2016 Q3	$246K	Hold	787	–	–	0.05%	81
2016 Q2	$190K	Sell	787 -40	-5%	-$10.5K	0.04%	82
2016 Q1	$214K	Sell	827 -60	-7%	-$15.8K	0.04%	87
2015 Q4	$272K	Hold	887	–	–	0.06%	35
2015 Q3	$259K	Hold	887	–	–	0.04%	50
2015 Q2	$358K	Buy	+887	New	+$356K	0.12%	42
2013 Q4	–	Sell	-467	Closed	-$112K	–	621
2013 Q3	$112K	Buy	+467	New	+$105K	0.02%	273

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Hirtle Callaghan & Co's BIIB Position: Q4 2017 in Review

Hirtle Callaghan & Co sold out of Biogen (BIIB) in Q4 2017, closing a stake of 88 shares — an estimated $28K sold.

Hirtle Callaghan & Co first reported a position in BIIB in Q3 2013 and held it in 11 quarters. The position peaked at $358K in Q2 2015. 1,123 funds tracked by Wall St. Rank hold BIIB as of Q4 2017.

Hirtle Callaghan & Co reported no remaining Biogen position as of Q4 2017 after selling out during the quarter.
Hirtle Callaghan & Co sold 88 Biogen shares in Q4 2017, an estimated $28K.
Hirtle Callaghan & Co first reported a position in Biogen in Q3 2013 and held it in 11 quarters.
Hirtle Callaghan & Co's Biogen position peaked at $358K in Q2 2015.
1,123 funds tracked by Wall St. Rank held Biogen as of Q4 2017.

Based on Hirtle Callaghan & Co's 13F filing for Q4 2017, filed 17 Jan 2018.